IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.8400
+0.0200 (2.44%)
At close: Aug 13, 2025, 4:00 PM
0.8400
0.00 (-0.01%)
After-hours: Aug 13, 2025, 6:51 PM EDT
Company Description
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.
The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors.
The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
IceCure Medical Ltd
| Country | Israel |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Eyal Shamir |
Contact Details
Address: 7 Ha’Eshel Street, PO Box 3163 Caesarea, 3079504 Israel | |
| Phone | 972 4 623 0333 |
| Website | icecure-medical.com |
Stock Details
| Ticker Symbol | ICCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 0001584371 |
| CUSIP Number | M53071136 |
| ISIN Number | IL0011224156 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eyal Shamir | Chief Executive Officer and Director |
| Ronen Tsimerman CPA | Chief Financial Officer and Chief Operating Officer |
| Tlalit Bussi Tel-Tzure | Vice President of Business Development and Global Marketing |
| Shad Good | Vice President of Sales for North America |
| Merav Nir Dotan | Vice President of Human Resources |
| Galit Malik | Vice President of Operations and Service |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 6-K | Report of foreign issuer |
| Aug 4, 2025 | EFFECT | Notice of Effectiveness |
| Aug 1, 2025 | 6-K/A | Filing |
| Aug 1, 2025 | POS AM | Post-Effective amendments for registration statement |
| Aug 1, 2025 | 6-K | Report of foreign issuer |
| Jul 28, 2025 | 424B3 | Prospectus |
| Jul 28, 2025 | 6-K | Report of foreign issuer |
| Jul 25, 2025 | 6-K | Report of foreign issuer |
| Jul 16, 2025 | 424B3 | Prospectus |
| Jul 16, 2025 | 6-K | Report of foreign issuer |